BioCentury
ARTICLE | Company News

Biotecnol S.A., INSERM, Hopitaux Universitaires de Strasbourg, Universite Louis Pasteur deal

February 9, 2009 8:00 AM UTC

The institutions granted Biotecnol an exclusive, worldwide license to develop and commercialize IP covering parathyroid hormone-related protein (PTHrP) antagonists to treat renal cell carcinoma (RCC)....